AnaptysBio (NASDAQ:ANAB) is a clinical-stage biotechnology company focused on developing transformative antibody therapeutics in inflammatory and immuno-oncology indications. Founded in 2011 and headquartered in San Diego, California, the company harnesses its proprietary Somatic Hypermutation (SHM) technology platform to generate high-affinity, humanized antibodies with optimized profiles for safety and efficacy. AnaptysBio’s scientific team has deep expertise in antibody engineering, immunology and translational medicine, driving innovative programs from discovery through clinical development.
The company’s pipeline spans multiple therapeutic areas, including immunology and rare diseases. Lead programs include an anti-interleukin-36 receptor antibody for generalized pustular psoriasis, and an anti-Siglec-8 antibody targeting eosinophil and mast cell-mediated disorders. Additional candidates are in development for indications such as chronic spontaneous urticaria, ulcerative colitis and hematologic malignancies. AnaptysBio applies its SHM platform to rapidly screen and optimize novel targets, delivering drug candidates with differentiated mechanisms of action and favorable developability attributes.
AnaptysBio operates research and development facilities in both the United States and Europe, supporting discovery, analytical characterization and early-stage clinical manufacturing. The company has established strategic collaborations, including a multi-target partnership with a leading global pharmaceutical firm to co-develop immuno-oncology antibodies. These alliances provide access to complementary expertise, expand the therapeutic reach of AnaptysBio’s platform and strengthen its clinical development capabilities.
Under the leadership of President and Chief Executive Officer David Hallal, AnaptysBio continues to advance its portfolio through Phase 1 and Phase 2 trials, with key clinical readouts anticipated across its immunology and oncology programs. The management team comprises seasoned drug developers, immunologists and bioprocessing experts committed to translating cutting-edge science into potential new therapies for patients with serious and life-threatening diseases.
